The m6A-independent role of epitranscriptomic factors in cancer.
Int J Cancer
; 2024 Jun 27.
Article
en En
| MEDLINE
| ID: mdl-38935523
ABSTRACT
Protein function alteration and protein mislocalization are cancer hallmarks that drive oncogenesis. N6-methyladenosine (m6A) deposition mediated by METTL3, METTL16, and METTL5 together with the contribution of additional subunits of the m6A system, has shown a dramatic impact on cancer development. However, the cellular localization of m6A proteins inside tumor cells has been little studied so far. Interestingly, recent evidence indicates that m6A methyltransferases are not always confined to the nucleus, suggesting that epitranscriptomic factors may also have multiple oncogenic roles beyond m6A that still represent an unexplored field. To date novel epigenetic drugs targeting m6A modifiers, such as METTL3 inhibitors, are entering into clinical trials, therefore, the study of the potential onco-properties of m6A effectors beyond m6A is required. Here we will provide an overview of methylation-independent functions of the m6A players in cancer, describing the molecular mechanisms involved and the future implications for therapeutics.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Int J Cancer
/
Int. j. cancer
/
International journal of cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Italia